Update on pharmacologic therapies for osteoporosis

Nurse Practitioner

Volumn 21, Issue 8, 1996, Pages 19-24

  Kessenich, Cathy R ^a  

^a HUSSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITONIN; FLUORIDE SODIUM;

BONE DENSITY; DRUG EFFECT; ESTROGEN THERAPY; HUMAN; OSTEOPOROSIS; REVIEW;

ALENDRONATE; BONE DENSITY; CALCITONIN; ESTROGEN REPLACEMENT THERAPY; HUMANS; OSTEOPOROSIS; SODIUM FLUORIDE;

EID: 0030202791     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1080/19966205-199608000-00003     Document Type: Article

References (18)

1. National Osteoporosis Foundation. Physicians’ resource manual on osteoporosis: a decision making model, 2nd ed. Washington, D.C.: National Osteoporosis Foundation, 1991.
2. Position paper: Current perspectives on diagnosis, prevention, and treatment of osteoporosis. Washington, D.C.: National Osteoporosis Foundation, 1995.
3. Riggs BL, Melton LJ: The prevention and treatment of osteoporosis. N Eng J Med 1992; 327:620-27.
4. Repa-Eschen LM: Prevention and treatment of osteoporosis in our healthcare delivery system. In: Avioli, ed. The Osteoporotic Syndrome, 3rd ed. New York: Wiley-Liss, 1993:191-209.
5. Cooper C, Kanis JA, Compston J. How to assess drug efficacy in osteoporosis. Lancet 1995; 345:743-44.
6. Tayler EM: Measurement of bone density in osteoporosis. BMJ 1995;311:263-64.
7. The choices for treating osteoporosis. The Johns Hopkins Mcdical Letter, Health After 50 1992; April:6-7.
8. Recker RR: Clinical review: Current therapy for osteoporosis. J Clin Endocrin & Metab 1993;76(1):14-16.
9. Lieberman UA, Weiss SR, Broil J, et al: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Eng J Med 1995; 33:1437-43.
10. Chestnut CH, McClung MR, Ensrud KE, et al: Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling: Am J Med 1995; 99:144-52.
11. Azria M: 25 years of salmon calcitonin: From synthesis to therapeutic use. Calcif Tissue Int 1995;57:405-8.
12. Foti R, Martorana U, Broggini M: Long-term tolerability of nasal spray formulation of salmon calcitonin. Curr Ther Res 1995; 56:429-35.
13. Overgaard IC, Riis BJ: Nasal salmon calcitonin in osteoporosis. Calcif Tissue Int 1994;55:79-81.
14. Cranney A, Moher D, Shea B, et al: Metaanalysis of calcitonin in the treatment of postmenopausal osteoporosis. Am Coll Rheum 1995;38:S360.
15. Riffee JM: Osteoporosis prevention and management. Am Pharm 1992; 8:61-70.
16. El-Choufi L, Nelson J, Kleerekoper M: Therapeutic options in osteoporosis. J Musculoskel Med 1994;11:15-21.
17. Pak YC, Kakhaee K, Adams-Huet B, et al: Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Ann Intern Med 1995; 123(6):401-8.
18. New drugs for osteoporosis. The Medical Letter on Drugs and Therapeutics 1996; Jan 5:1-3.